Medtronic PLC Company Profile (NYSE:MDT)

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Medtronic PLC declared a quarterly dividend on Monday, August 28th. Stockholders of record on Friday, September 29th will be given a dividend of $0.46 per share on Friday, October 20th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date of this dividend is Thursday, September 28th. View Medtronic PLC's Dividend History.

Medtronic PLC (NYSE:MDT) announced its quarterly earnings data on Tuesday, August, 22nd. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.08 by $0.04. The business had revenue of $7.39 billion for the quarter, compared to analysts' expectations of $7.44 billion. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. Medtronic PLC's quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the firm posted $1.03 EPS. View Medtronic PLC's Earnings History.

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Medtronic PLC.

21 brokerages have issued 12-month target prices for Medtronic PLC's stock. Their forecasts range from $78.00 to $96.00. On average, they anticipate Medtronic PLC's stock price to reach $88.82 in the next year. View Analyst Ratings for Medtronic PLC.

Here are some recent quotes from research analysts about Medtronic PLC stock:

• 1. According to Zacks Investment Research, "Over the last three months, Medtronic has been observed to underperform the broader industry. We note that, escalating costs and expenses are weighing on margins. Also, unfavorable foreign exchange continues to remain a drag. On a positive note,  we observe that apart from displaying successful integration and achievement of synergy targets, Medtronic’s major business groups continue to contribute to top-line growth which highlighted sustainability across all segments and geographies. Recently, the company announced the receipt of regulatory approval from the Japanese MHLW for its IN.PACT Admiral Drug-Coated Balloon. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside. We are also encouraged by the solid growth trend, continuing in the U.S. as well as the healthy global acceptance of its advanced therapies." (9/12/2017)
• 2. Needham & Company LLC analysts commented, "F4Q17 revenue and EPS beat consensus and initial FY18 guidance was in line with consensus. Organic revenue growth was steady at 4.0% vs. 4.1% in F3Q17 with new products adding ~370 bps, emerging markets adding ~125 bps and services & solutions adding ~15 bps. Operating margin was above consensus and up 10 bps Y/Y (or 40 bps Y/Y CC). MDT’s product cycle remains strong with significant FY18 launches including: the Resolute Onyx DES, MiniMed 670G insulin pump, Signia powered stapler, new LigaSure instruments, Intellis spinal cord stimulator, Evolut PRO TAVR, and MRI CRT-P quadripolar system." (5/25/2017)
• 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
• 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)

Some companies that are related to Medtronic PLC include Pfizer (PFE), Novartis AG (NVS), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), AbbVie (ABBV), Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), Thermo Fisher Scientific (TMO), Allergan PLC. (AGN) and Biogen (BIIB).

Medtronic PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.71%), BlackRock Inc. (6.59%), State Street Corp (4.53%), FMR LLC (3.80%), Franklin Resources Inc. (2.81%) and Capital Research Global Investors (2.31%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic PLC.

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Capital Research Global Investors, State Street Corp, Capital Guardian Trust Co., Dodge & Cox, Standard Life Investments LTD and Bank of New York Mellon Corp. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic PLC.

Medtronic PLC's stock was acquired by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Alliancebernstein L.P., BlackRock Inc., Vanguard Group Inc., Sanders Capital LLC, Principal Financial Group Inc., Koch Industries Inc. and American Century Companies Inc.. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic PLC.

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Medtronic PLC stock can currently be purchased for approximately $79.70.